SCHEMBL7166309

SCHEMBL7166309

N#Cc1ccc(S(=O)(=O)CCCN2CC3CCOC(C2)CN(Cc2ccc(F)cc2)C3)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.39
DRD3 P35462 5/20 0.39
HTR2A P28223 4/20 0.38
DRD4 P21917 4/20 0.38
CACNA1F O60840 2/20 0.38
HTR1A P08908 2/20 0.38
ADORA3 P0DMS8 2/20 0.38
DRD1 P21728 2/20 0.38
DRD5 P21918 2/20 0.38
HRH2 P25021 2/20 0.38
ADRA1D P25100 2/20 0.38
HTR7 P34969 2/20 0.38
ADRA1A P35348 2/20 0.38
HRH1 P35367 2/20 0.38
ADRA1B P35368 2/20 0.38
OPRM1 P35372 2/20 0.38
HTR6 P50406 2/20 0.38
CACNA1D Q01668 2/20 0.38
SLC6A3 Q01959 2/20 0.38
CACNA1S Q13698 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2963311 0.88 KCNH2 (0.47) DRD2DRD3HTR2ADRD4CACNA1F
SCHEMBL6997428 0.86 DRD2 (0.41) DRD2DRD3HTR2ADRD4CACNA1F
SCHEMBL5965538 0.81 DRD3 (0.40) DRD2DRD3HTR2ADRD4CACNA1F
SCHEMBL2961534 0.75 KCNH2 (0.52) DRD2HTR2AHTR2CCCR3KCNH2
SCHEMBL3130292 0.74 KCNH2 (0.55) DRD2DRD3HTR2ADRD4HTR1A
SCHEMBL7248526 0.72 NSD2 (0.40) DRD2DRD3HTR2ADRD4CACNA1F
SCHEMBL3124734 0.71 KCNH2 (0.57) DRD2DRD3KCNH2THRBPRKAA2
SCHEMBL3129028 0.71 KCNH2 (0.57) DRD2DRD3KCNH2THRBPRKAA2
SCHEMBL2966844 0.71 KCNH2 (0.41) DRD2DRD3HRH2HTR7HRH1
SCHEMBL7166109 0.71 HRH3 (0.44) HRH2HRH1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559143-B1 Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction ASTRAZENECA AB (SE) 2003-05-06 US claimed